SLC6A19 and phenylketonuria: These data are in line with genetic data showing that heterozygous loss of Slc6a19 is insufficient to lower plasma Phe in Pahenu2 mice and suggest that steady-state exposures above the IC90 may be desired to exercise the maximal pharmacological effect on liberation of excess Phe in a clinical PKU setting.